Cyclophosphamide
Cyclophosphamide is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Cyclophosphamide; Generic name: CYCLOPHOSPHAMIDE; Manufacturer: Cipla USA Inc..
| Brand name | Cyclophosphamide |
|---|---|
| Generic name | CYCLOPHOSPHAMIDE |
| Manufacturer | Cipla USA Inc. |
| Used for | 1 INDICATIONS AND USAGE Cyclophosphamide capsules, USP is an alkylating drug indicated for treatment of: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome i |
| Dosage | 2 DOSAGE AND ADMINISTRATION During or immediately after the administration, administer adequate amounts of fluid to reduce the risk of urinary tract toxicity ( 2.1 ). Malignant Diseases: Adult and Pediatric Patients ( 2.2 ) Oral: Usually 1 mg per kg per day to 5 mg per kg orally once daily for both initial and maintenance dosing. Minimal Change Nephrotic Syndrome in Pediatric Patients ( 2.3 ) Recommended oral dose: 2 mg per kg once daily for 8 to 12 weeks (maximum cumulative dose 168 mg per kg). |
| Active ingredient(s) | CYCLOPHOSPHAMIDE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e1cb955-99c8-4fe5-89d1-399c8e52174e |